Lupin and Gan & Lee have an exclusive China agreement for the diabetic medication bofanglutide.

On Monday, December 29, the pharmaceutical company Lupin Ltd announced that it has signed an exclusive license, supply, and distribution contract for bofanglutide, a novel weekly GLP-1 receptor agonist, with Gan & Lee Pharmaceuticals, a Chinese company. The arrangement is intended to increase Lupin's market share in the obese market and boost its diabetic portfolio. Gan & Lee's bofanglutide injection is intended for adults with type 2 diabetes and helps people who are overweight or obese control their weight.